While Pfizer's market cap and dividends are at risk, Novo has a strong competitive position in GLP-1 TAM. Read why I prefer ...

In valuation, RIO is quoted at a discount compared to its peers. Its P/E FWD is 11.1x vs the industry’s 18.8x, 41% lower, and ...